^
Association details:
| Biomarker: | SLC8A1-PKDCC-ALK fusion + ALK overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Qi Xinke (iruplinalkib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
Published date:
06/30/2022
Excerpt:
A 47-year-old Chinese female patient diagnosed with IVB lung adenocarcinoma...A novel ALK rearrangement generated by a fusion of the intergenic region between SLC8A1 and PKDCC to the intron 19 of ALK was presented after next-generation sequencing and was further confirmed by Sanger’s sequencing. High expression of ALK was revealed by immunohistochemistry....and received an orally active second-generation ALK inhibitor WX-0593. Over the course of 17 months, the partial response was obtained without significant side effects.
DOI:
https://doi.org/10.3389/fonc.2022.898954
